Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 9:28 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1417–1440 of 3,451 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Colorectal Cancer Clear all

Conditions: Squamous Cell Carcinoma of Head and Neck, Colo-rectal Cancer, Non Small Cell Lung Cancer, Transitional Cell Carcinoma of the Bladder, Other Solid Tumors, Clear Cell Renal Cell Carcinoma
Interventions: HC-7366; Drug
Lead sponsor: HiberCell, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 7
States / cities: La Jolla, California • Aurora, Colorado • St Louis, Missouri + 3 more

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Stage I Colorectal Cancer AJCC v8, Stage I Prostate Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
Interventions: Exercise Intervention, Informational Intervention, Nutritional Assessment, Physical Performance Testing, Quality-of-Life Assessment, Questionnaire Administration; Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 65 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Cancer of Colon, Cancer of Rectum
Interventions: Colorectal Health Research Champions; Behavioral
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 30 Years to 99 Years
Enrollment: 91 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Solid Tumors, Non-small Cell Lung Cancer, Castration Resistant Prostate Cancer, Microsatellite Stable Colorectal Cancer
Interventions: Navarixin, Pembrolizumab; Drug · Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 5
States / cities: Scottsdale, Arizona • Sarasota, Florida • Baltimore, Maryland + 2 more

Conditions: Colorectal Cancer, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Interventions: Fam-Trastuzumab Deruxtecan-Nxki; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Colorectal Cancer, Sarcomas, Metastatic Prostate Cancer, Ovarian Cancer, Small Cell Lung Cancer, Metastatic Breast Cancer, Pancreas Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Cervical Cancer, Adenoid Cystic Carcinoma, Salivary Gland Cancer, Urothelial Carcinoma
Interventions: ONC-392, Pembrolizumab, Docetaxel; Drug
Lead sponsor: OncoC4, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 733 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 33
States / cities: Springdale, Arkansas • Davis, California • Downey, California + 27 more

Conditions: Metastatic Colorectal Cancer
Interventions: Trastuzumab, Cetuximab, Neratinib, Guardant360 Diagnostic Test; Drug · Diagnostic Test
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 48
States / cities: Anaheim, California • Baldwin Park, California • Bellflower, California + 40 more

Conditions: Colon Adenocarcinoma, Stage IIA Colon Cancer AJCC v8
Interventions: Capecitabine, Fluorouracil, Leucovorin, Leucovorin Calcium, Oxaliplatin, Patient Observation; Drug · Other
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 635 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 932
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 639 more

Conditions: Colorectal Cancer, Epithelial Ovarian Cancer, Gastric Cancer, Invasive Lobular Breast Carcinoma, Pancreatic Ductal Adenocarcinoma
Interventions: [18F]FPyQCP; Drug
Lead sponsor: Blue Earth Diagnostics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: New York, New York • Dallas, Texas

Conditions: Squamous Cell Carcinoma of Head and Neck (SCCHN), Metastatic Colorectal Cancer
Interventions: INC280, cetuximab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 3
States / cities: Boston, Massachusetts • New York, New York • Salt Lake City, Utah

Conditions: Decision Aid
Interventions: Visual Array, Narrative Visual Array, Choice, Enhanced Choice; Behavioral
Lead sponsor: Stephanie B. Seminara, MD; Other
Eligibility: 18 Years and older
Enrollment: 1,045 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Colorectal Cancer
Interventions: Regorafenib (Stivarga, BAY73-4506), Nivolumab (Opdivo); Drug · Biological
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 15
States / cities: Duarte, California • Denver, Colorado • Miami, Florida + 12 more

Conditions: Colorectal Cancer
Interventions: Colonoscopy; Procedure
Lead sponsor: Oslo University Hospital; Other
Eligibility: 55 Years to 64 Years
Enrollment: 95,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2036
U.S. locations: 2
States / cities: Boston, Massachusetts • New York, New York

Conditions: Rectal Cancer
Interventions: Not listed
Lead sponsor: Power Life Sciences Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Colorectal Cancer, Pancreatic Cancer
Interventions: KRAS peptide vaccine, Nivolumab, Ipilimumab; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Colorectal Neoplasms
Interventions: Acupuncture; Procedure
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Colorectal Cancer, Neurotoxicity
Interventions: calcium gluconate, magnesium sulfate, placebo; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 14
States / cities: Augusta, Georgia • Des Moines, Iowa • Bismarck, North Dakota + 1 more

Conditions: Rectal Cancer
Interventions: Metabolic Imaging; Procedure
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Stanford, California

Conditions: Lung Cancer, Breast Cancer, Colon Cancer, Bladder Cancer, Hepatocellular Cancer
Interventions: SAFER TRACKS Intervention; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 2
States / cities: Houston, Texas • White River Junction, Vermont

Conditions: Chemotherapy Induced Neuropathic Pain, Chemotherapy Induced Pain Neuropathy, Chemotherapy Induced Pain
Interventions: Halneuron, Placebo, Halneuron (Open Label Extension); Drug
Lead sponsor: Dogwood Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 25
States / cities: Sheffield, Alabama • Glendale, Arizona • Phoenix, Arizona + 21 more

Conditions: Major Advanced Solid Tumors Other Than Colorectal
Interventions: PM01183; Drug
Lead sponsor: PharmaMar; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 2
States / cities: Aurora, Colorado • Chicago, Illinois

Conditions: Small Bowel Cancers, Colorectal Cancers
Interventions: CV301, MSB0011359C, N-803, NHS-IL12; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Colorectal Cancer
Interventions: fluorouracil, leucovorin calcium; Drug
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 859 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1993 – 2015
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: BRAF NP_004324.2:p.V600E, Metastatic Colon Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma, Progressive Disease, Recurrent Colorectal Carcinoma, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8, Unresectable Colon Adenocarcinoma, Unresectable Rectal Adenocarcinoma
Interventions: Cetuximab, Encorafenib, Nivolumab; Biological · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)

Online Dietary and Resistance Training to Improve Physical Function in Older Cancer Survivors, E-PROOF Trial

Colorectal Health Research Champions

Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)

A Study of Trastuzumab Deruxtecan (T-DXd) and Cetuximab in People With Colorectal Cancer

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status

Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery

[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications

Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy

Using Visual Arrays to Support Understanding of Genetic Risk

Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable)

The Northern-European Initiative on Colorectal Cancer

Taking a Look at Patient Experiences In Rectal Cancer Clinical Trials

Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer

Acupuncture to Reduce Symptoms of Advanced Colorectal Cancer

Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity Caused By Oxaliplatin in Patients Receiving Combination Chemotherapy for Stage II, Stage III, or Stage IV Colorectal Cancer That Has Been Completely Removed By Surgery

Metabolic Imaging Predict Histopathologic Response to Preop ChemoXRT for Locally Advanced Rectal CA

Measuring and Improving the Safety of Test Result Follow-Up

Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain

Study of PM01183 in Non-Colorectal Cancer Patients as a Days 1 and 8 Intravenous Short Infusion Every 3 Weeks

Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers

Perioperative Chemotherapy in Treating Patients With Colon Cancer That Can Be Surgically Removed

Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer